<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) and atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> have an increased risk for <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, there is little knowledge about the long-term fate of atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> and the incidence of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> in patients receiving continued oral anticoagulation </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-three consecutive patients with AF and atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were enrolled in the study </plain></SENT>
<SENT sid="3" pm="."><plain>Serial and prospective transesophageal echocardiographic studies, cranial magnetic resonance imaging (MRI), and clinical examinations were performed during a period of 12 months </plain></SENT>
<SENT sid="4" pm="."><plain>Oral anticoagulation was continued or initiated in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="5" pm="."><plain>An international normalized ratio of 2.0 to 3.0 was regarded as effective </plain></SENT>
<SENT sid="6" pm="."><plain>During follow-up, 56% of the <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> disappeared (7 [16%] at 1 month, 18 [42%] at 3 months, 21 [49%] at 6 months, and 24 [56%] at 12 months) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with the disappearance of <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> had significantly smaller <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> compared with patients with persistent <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> (1.5 +/- 0.8 cm in length and 0.8 +/- 0.5 cm in width vs 1.9 +/- 0.6 cm in length and 1.3 +/- 0.4 cm in width, p = 0.04), reduced echogenicity of <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> (46% vs 89%, p &lt;0.01), and smaller left atrial (LA) volume (83 +/- 27 vs 116 +/- 55 cm(3)) </plain></SENT>
<SENT sid="8" pm="."><plain>Seven patients (16%) had embolic lesions during follow-up MRI </plain></SENT>
<SENT sid="9" pm="."><plain>Six of these patients (86%) had clinically apparent embolisms, and 1 died from <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>The only independent predictors of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> were an elevated peak emptying velocity of the LA appendage (p &lt;0.01) and previous <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> (p = 0.02) </plain></SENT>
<SENT sid="11" pm="."><plain>Patients with AF and atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> have a large likelihood of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> (16%) and/or <z:hpo ids='HP_0011420'>death</z:hpo> despite oral anticoagulation therapy </plain></SENT>
<SENT sid="12" pm="."><plain><z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> size may predict <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> resolution under continued anticoagulation </plain></SENT>
</text></document>